Decapeptyl Use In Pregnancy & Lactation

Pregnancy: Prior to treatment, potentially fertile women should be examined carefully to exclude pregnancy.
Triptorelin should not be used during pregnancy since concurrent use of GnRH agonists is associated with a theoretical risk of abortion or foetal abnormality. Very limited data on the use of triptorelin during pregnancy do not indicate an increased risk of congenital malformations. However, long-term follow-up studies on development are too limited. Animal data do not indicate direct or indirect harmful effects with respect to pregnancies or postnatal developments, but there are indications for delayed fetal development and parturition (see Pharmacology: Toxicology: Preclinical safety data under Actions). Based on the pharmacological effects, disadvantageous, influence on the pregnancy and the offspring cannot be excluded and DECAPEPTYL should not be used during pregnancy. Non-hormonal methods of contraception should be employed during therapy until menses resume. If a patient becomes pregnant while receiving triptorelin, therapy should be discontinued.
When triptorelin is used for infertility treatment, there is no clinical evidence to suggest a causal connection between triptorelin and any subsequent abnormalities of oocyte development or pregnancy or outcome.
Lactation: It is not known whether triptorelin is excreted in human milk. Because of the potential for adverse reactions from triptorelin in nursing infants, breastfeeding should be discontinued prior to and throughout administration.